Betaine and secondary events in an acute coronary syndrome cohort

PLoS ONE

Volumn 7, Issue 5, 2012, Pages

  Lever, Michael ^a,b   George, Peter M ^a,b   Elmslie, Jane L ^a   Atkinson, Wendy ^a   Slow, Sandy ^a,b   Molyneux, Sarah L ^a   Troughton, Richard W ^b   Richards, A Mark ^b   Frampton, Christopher M ^b   Chambers, Stephen T ^b  

^a CANTERBURY HEALTH LABORATORIES   (New Zealand)

^b UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETAINE; DIMETHYLGLYCINE; HOMOCYSTEINE; DRUG DERIVATIVE; SARCOSINE;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; BLOOD LEVEL; BLOOD SAMPLING; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMORBIDITY; CONCENTRATION (PARAMETERS); DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEART FAILURE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; RECURRENCE RISK; RISK ASSESSMENT; SURVIVAL; URINALYSIS; URINARY EXCRETION; URINE LEVEL; BLOOD; HEART INFARCTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; NEW ZEALAND; RISK FACTOR; STATISTICAL MODEL; URINE;

ACUTE CORONARY SYNDROME; AGED; AGED, 80 AND OVER; BETAINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COHORT STUDIES; FEMALE; HEART FAILURE; HOMOCYSTEINE; HUMANS; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NEW ZEALAND; RISK FACTORS; SARCOSINE;

EID: 84861387300     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0037883     Document Type: Article

References (49)

1. Craig SAS, (2004) Betaine in human nutrition. Am J Clin Nutr 80: 539-549.
2. Ueland PM, Holm PI, Hustad S, (2005) Betaine: a key modulator of one-carbon metabolism and homocysteine status. Clin Chem Lab Med 43: 1069-1075.
3. Lever M, Slow S, (2010) The clinical significance of betaine, an osmolyte with a key role in methyl group metabolism. Clin Biochem 43: 732-744.
4. Ueland PM, (2011) Choline and betaine in health and disease. J Inherit Metab Dis 34: 3-15.
5. Ratriyanto A, Mosenthin R, Bauer E, Eklund M, (2009) Metabolic, osmoregulatory and nutritional functions of betaine in monogastric animals. Asian-Austral J Animal Sci 22: 1461-1476.
6. Lever M, George PM, Dellow WJ, Scott RS, Chambers ST, (2005) Homocysteine, glycine betaine, and N,N-dimethylglycine in patients attending a lipid clinic. Metabolism 54: 1-14.
7. Konstantinova SV, Tell GS, Vollset SE, Ulvik A, Drevon CA, et al. (2008) Dietary patterns, food groups, and nutrients as predictors of plasma choline and betaine in middle-aged and elderly men and women. Am J Clin Nutr 88: 1663-1669.
8. Lever M, George PM, Atkinson W, Molyneux SL, Elmslie JL, et al. (2011) Plasma lipids and betaine are related in an acute coronary syndrome cohort. PLoS One 6 (7): e21666.
9. Slow S, Lever M, Chambers ST, George PM, (2009) Plasma dependent and independent accumulation of betaine in male and female rat tissues. Physiol Res 58: 403-410.
10. Schwab U, Törrönen A, Meririnne E, Saarinen M, Alfthan G, et al. (2006) Orally administered betaine has an acute and dose-dependent effect on serum betaine and plasma homocysteine concentrations in healthy humans. J Nutr 136: 34-38.
11. Atkinson A, Slow S, Elmslie J, Lever M, Chambers ST, et al. (2009) Dietary and supplementary betaine: effects on betaine and homocysteine concentrations in males. Nutr Metab Cardiovasc Dis 19: 767-773.
12. Lever M, Sizeland PC, Frampton CM, Chambers ST, (2004) Short and long-term variation of plasma glycine betaine concentrations in humans. Clin Biochem 37: 184-190.
13. Lever M, Atkinson W, Sizeland PCB, Chambers ST, George PM, (2007) Inter- and intra-individual variations in normal urinary glycine betaine excretion. Clin Biochem 40: 447-453.
14. Lever M, Atkinson W, Slow S, Chambers ST, George PM, (2009) Plasma and urine betaine and dimethylglycine variation in healthy young male subjects. Clin Biochem 42: 706-712.
15. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, et al. (2011) Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472: 57-63.
16. Holm PI, Bleie Ø, Ueland PM, Lien EA, Refsum H, et al. (2004) Betaine as a determinant of postmethionine load total plasma homocysteine before and after B-vitamin supplementation. Arterioscler Thromb Vasc Biol 24: 301-307.
17. Bønaa KH, Njølstad I, Ueland PM, Schirmer H, Tverdal A, et al. (2006) Homocysteine lowering and cardiovascular events after acute myocardial infarction. New Engl J Med 354: 1578-1588.
18. The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators (2006) Homocysteine lowering with folic acid and B vitamins in vascular disease. New Engl J Med 354: 1567-77.
19. Albert CM, Cook NR, Gaziano JM, Zaharris E, MacFadyen J, et al. (2008) Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial. JAMA 299: 2027-2036.
20. Shewan LG, Coats AJ, (2010) Ethics in the authorship and publishing of scientific articles. Int J Cardiol; 144: 1-2.
21. Ellis KL, Newton-Cheh C, Wang TJ, Frampton CM, Doughty RN, et al. (2011) Association of genetic variation in the natriuretic peptide system with cardiovascular outcomes. J Mol Cell Cardiol 50: 695-701.
22. Remme WJ, Swedberg K, for the Task Force for the Diagnosis and Treatment of Chronic Heart Failure, European Society of Cardiology (2001) Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 22: 1527-1560.
23. Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, et al. (2007) Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Amer Col Cardiol 50: e1-e157.
24. De Lemos JA, Morrow DA, Bentley JH, Omland T, Sabatine MS, et al. (2001) The prognostic value of B-type natriuretic peptides in patients with acute coronary syndromes. New Engl Med J 345: 1014-1021.
25. Storer MK, Lever M, (2006) Aracyl triflates for preparing fluorescent and UV absorbing derivatives of unreactive carboxylates, amines and other metabolites. Anal Chim Acta 558: 319-325.
26. Storer MK, McEntyre CJ, Lever M, (2006) Separation of cationic aracyl derivatives of betaines and related compounds. J Chromatogr A 1104: 263-271.
27. Richards A, Nicholls M, Yandle T, Ikram H, Espiner EA, et al. (1999) Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. Heart 81: 114-120.
28. Lever M, George PM, Slow S, Elmslie JL, Scott RS, et al. (2009) Fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine. Cardiovasc Drugs Ther 23: 395-401.
29. Lever M, Atkinson W, Chambers ST, George PM, (2007) An abnormal urinary excretion of glycine betaine may persist for years. Clin Biochem 40: 798-801.
30. Smulders YM, Blom HJ, (2011) The homocysteine controversy. J Inherit Metab Dis 34: 93-99.
31. de Ruijter W, Westendorp RG, Assendelft WJ, den Elzen WPJ, de Craen AJM, et al. (2009) Use of framingham risk score and new biomarkers to predict cardiovascular mortality in older people: population based observational cohort study. BMJ 338: a3083.
32. Wald DS, Morris JK, Wald NJ, (2011) Reconciling the Evidence on Serum Homocysteine and Ischaemic Heart Disease: A Meta-Analysis. PLoS One 6 (2): e16473.
33. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, et al. (2004) Impact of obesity on plasma natriuretic peptide levels. Circulation 109: 594-600.
34. Krupièka J, Janota T, Kasalová Z, Hradec J, (2009) Natriuretic Peptides - Physiology, Pathophysiology and Clinical Use in Heart Failure. Physiol Res 58: 171-177.
35. Guéant Rodriguez RM, Spada R, Pooya S, Jeannesson E, Moreno Garcia MA, et al. (2012) Homocysteine predicts increased NT-pro-BNP through impaired fatty acid oxidation. Int J Cardiol in press. doi:10.1016/j.ijcard.2012.03.047.
36. Lever M, Sizeland PC, Bason LM, Hayman CM, Robson RA, et al. (1994) Abnormal glycine betaine content of the blood and urine of diabetic and renal patients. Clin Chim Acta 230: 69-79.
37. Sizeland PCB, Chambers ST, Lever M, Bason LM, Robson RA, (1995) Short-term response of nonurea organic osmolytes in human kidney to a water load and water deprivation. Am J Physiol 268 (Renal Fluid Electrolyte Physiol 37): F227-F233.
38. Beck F-X, Burger-Kentischer A, Müller E, (1998) Cellular response to osmotic stress in the renal medulla. Pflügers Arch - Eur J Physiol 436: 814-827.
39. Wettstein M, Peters-Regehr T, Kubitz R, Fischer R, Holneicher C, et al. (2000) Release of osmolytes induced by phagocytosis and hormones in rat liver. Am J Physiol (Gastrointest Liver Physiol) 278: G227-G233.
40. Strakova J, Williams KT, Gupta S, Schalinske KL, Kruger WD, et al. (2010) Dietary intake of S-(α-carboxybutyl)-DL-homocysteine induces hyperhomocysteinemia in rats. Nutr Res 30: 492-500.
41. Teng Y-W, Mehedint MG, Garrow TA, Zeisel SH, (2011) Deletion of betaine-homocysteine S-methyltransferase in mice perturbs choline and 1-carbon metabolism, resulting in fatty liver and hepatocellular carcinomas. J Biol Chem 286: 36258-36267.
42. Lever M, Slow S, George PM, Chambers ST, (2012) Betaine excretion correlates with plasma homocysteine when plasma lipids are elevated. Clin Biochem 45: 154-156.
43. Lever M, George PM, Atkinson W, Elmslie JL, Slow S, et al. (2012) The contrasting relationships between betaine and homocysteine in two clinical cohorts are associated with plasma lipids and drug treatments. PLoS One 7 (3): e32460.
44. Schwab U, Alfthan G, Uusitupa M, (2011) Long-term effect of betaine on risk factors associated with the metabolic syndrome in healthy subjects. Eur J Clin Nutr 65: 70-76.
45. Schwahn BC, Wang X-L, Mikael LG, Wu Q, Cohn J, et al. (2007) Betaine supplementation improves the atherogenic risk factor profile in a transgenic mouse model of hyperhomocysteinemia. Atherosclerosis 195: e100-107.
46. Lv S, Hou M, Tang Z, Ling W, Zhu H, (2009) Betaine supplementation attenuates atherosclerotic lesion in apolipoprotein E-deficient mice. Eur J Nutr 48: 205-212.
47. Armstrong LE, Casa DJ, Roti MW, Lee EC, Craig SAS, et al. (2008) Influence of betaine consumption on strenuous running and sprinting in a hot environment. J Strength Cond Res 22: 851-860.
48. Hoffman J, Ratamess N, Kang J, Rashti S, Faigenbaum A, (2009) Effect of betaine supplementation on power performance and fatigue. J Internat Soc Sports Nutr 6: 7.
49. Lee EC, Maresh CM, Kraemer WJ, Yamamoto LM, Hatfield DL, et al. (2010) Ergogenic effects of betaine supplementation on strength and power performance. J Internat Soc Sports Nutr 7: 27.